Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Foscan NDA accepted for review

Dec. 3, 1999

Liposomal vinorelbine: design and preliminary characterization in vitro and in vivo

Dec. 1, 1999

Eukarion awarded SBIR grant to develop treatment for radiation damage

Dec. 1, 1999

MMP inhibitor NF-681 targets renal cell carcinoma

Dec. 1, 1999

Team from P&G discovers new use for an old drug

Dec. 1, 1999

Efficacy of FXR-targeting therapy validated by Symphar-Ilex team

Dec. 1, 1999

3-DP investigators study role of MMP in tumor angiogenesis

Nov. 30, 1999

Sindan and Pfizer team up to develop new multitargeted antifolate

Nov. 30, 1999

Ligand applies for E.U. marketing approval of Targretin as CTCL therapy

Nov. 30, 1999

First toxicity, pharmacokinetic data for JAK3 inhibitors presented at recent scientific meeting

Nov. 30, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...